Cargando…

Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of KRAS-mutant colorectal cancer

OBJECTIVE: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and PI3K/AKT pathways. Effective targeted therapies are urgently needed. We investigated whether rigosertib, a benzyl styryl sulfone RAS sig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xinyi, Xiao, Qian, Fu, Dongliang, Zhang, Haochen, Tang, Yang, He, Jinjie, Hu, Yeting, Kong, Xiangxing, Teng, Fei, Liu, Xiangrui, Yuan, Ying, Ding, Kefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832955/ https://www.ncbi.nlm.nih.gov/pubmed/34347396 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0532

Ejemplares similares

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
por: Yang, Hang, et al.
Publicado: (2022)

Prognostic Risk Model of Immune-Related Genes in Colorectal Cancer
por: Qian, Yucheng, et al.
Publicado: (2021)

The Disulfiram/Copper Complex Induces Autophagic Cell Death in Colorectal Cancer by Targeting ULK1
por: Hu, Yeting, et al.
Publicado: (2021)

Rigosertib ameliorates the effects of oncogenic KRAS signaling in a murine model of myeloproliferative neoplasia
por: Baker, Stacey J., et al.
Publicado: (2019)

Rigosertib and Cholangiocarcinoma: A Cell Cycle Affair
por: Malacrida, Alessio, et al.
Publicado: (2021)

Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
por: Dietrich, Peter, et al.
Publicado: (2017)

Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent
por: Jost, Marco, et al.
Publicado: (2020)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Another Brick to Confirm the Efficacy of Rigosertib as Anticancer Agent
por: Malacrida, Alessio, et al.
Publicado: (2023)

A modified TNM staging system for non-metastatic colorectal cancer based on nomogram analysis of SEER database
por: Kong, Xiangxing, et al.
Publicado: (2018)

MICA (∗)012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
por: Ding, Weifeng, et al.
Publicado: (2020)

Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer
por: Liu, Yue, et al.
Publicado: (2017)

A predictive model for early recurrence of colorectal-cancer liver metastases based on clinical parameters
por: Dai, Siqi, et al.
Publicado: (2021)

Cohort profile: The National Colorectal Cancer Cohort (NCRCC) study in China
por: Zhu, Yingshuang, et al.
Publicado: (2021)

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer
por: Fernández Montes, A., et al.
Publicado: (2022)

Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na)
por: Monfort-Vengut, Ana, et al.
Publicado: (2023)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Synergistic blocking of RAS downstream signaling and epigenetic pathway in KRAS mutant pancreatic cancer
por: Zhang, Xiaofei, et al.
Publicado: (2022)

BEX2 promotes tumor proliferation in colorectal cancer
por: Hu, Yeting, et al.
Publicado: (2017)

Rigosertib inhibits MEK1–ERK pathway and alleviates lipopolysaccharide‐induced sepsis
por: Wang, Yin, et al.
Publicado: (2021)

In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells
por: Malacrida, Alessio, et al.
Publicado: (2021)

Silencing of brain-expressed X-linked 2 (BEX2) promotes colorectal cancer metastasis through the Hedgehog signaling pathway
por: Tan, Yinuo, et al.
Publicado: (2020)

RAS specific protease induces irreversible growth arrest via p27 in several KRAS mutant colorectal cancer cell lines
por: Stubbs, Caleb K., et al.
Publicado: (2021)

Identifying Stage II Colorectal Cancer Recurrence Associated Genes by Microarray Meta-Analysis and Building Predictive Models with Machine Learning Algorithms
por: Lu, Wei, et al.
Publicado: (2021)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Drug screening in human physiologic medium identifies uric acid as an inhibitor of rigosertib efficacy
por: Rawat, Vipin, et al.
Publicado: (2023)

Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients
por: Banda, Malathi
Publicado: (2015)

Spatially varying effects of predictors for the survival prediction of nonmetastatic colorectal Cancer
por: Tian, Yu, et al.
Publicado: (2018)

Incidence, Surgical Treatment, and Prognosis of Anorectal Melanoma From 1973 to 2011: A Population-Based SEER Analysis
por: Chen, Haiyan, et al.
Publicado: (2016)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma
por: Wei, Jingsun, et al.
Publicado: (2021)

Synthesis and antitumor effects of novel benzyl naphthyl sulfoxide/sulfone derivatives derived from Rigosertib
por: Tang, Lin, et al.
Publicado: (2021)

Asparagine synthetase and G-protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
por: Lu, Lingeng, et al.
Publicado: (2023)

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis
por: Tan, Yinuo, et al.
Publicado: (2019)

ANGPTL1 attenuates colorectal cancer metastasis by up-regulating microRNA-138
por: Chen, Haiyan, et al.
Publicado: (2017)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms
por: Lu, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_10dg8ldn5bk7fufon0bqsn0684